Notice: This company has been marked as potentially delisted and may not be actively trading. Audentes Therapeutics (BOLD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrends BOLD vs. SLN, HURA, VSTM, PGEN, DMAC, NLTX, MGNX, FULC, BMEA, and CLYMShould you be buying Audentes Therapeutics stock or one of its competitors? The main competitors of Audentes Therapeutics include Silence Therapeutics (SLN), TuHURA Biosciences (HURA), Verastem (VSTM), Precigen (PGEN), DiaMedica Therapeutics (DMAC), Neoleukin Therapeutics (NLTX), MacroGenics (MGNX), Fulcrum Therapeutics (FULC), Biomea Fusion (BMEA), and Climb Bio (CLYM). These companies are all part of the "pharmaceutical preparations" industry. Audentes Therapeutics vs. Silence Therapeutics TuHURA Biosciences Verastem Precigen DiaMedica Therapeutics Neoleukin Therapeutics MacroGenics Fulcrum Therapeutics Biomea Fusion Climb Bio Silence Therapeutics (NASDAQ:SLN) and Audentes Therapeutics (NASDAQ:BOLD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations. Do analysts rate SLN or BOLD? Silence Therapeutics presently has a consensus target price of $57.20, indicating a potential upside of 731.40%. Audentes Therapeutics has a consensus target price of $23.00, indicating a potential upside of 788.03%. Given Audentes Therapeutics' higher possible upside, analysts clearly believe Audentes Therapeutics is more favorable than Silence Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Audentes Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is SLN or BOLD more profitable? Audentes Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -342.00%. Silence Therapeutics' return on equity of -62.81% beat Audentes Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silence Therapeutics-342.00% -62.81% -33.89% Audentes Therapeutics N/A -321.10%-40.02% Does the MarketBeat Community favor SLN or BOLD? Audentes Therapeutics received 431 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 81.25% of users gave Silence Therapeutics an outperform vote while only 69.12% of users gave Audentes Therapeutics an outperform vote. CompanyUnderperformOutperformSilence TherapeuticsOutperform Votes3981.25% Underperform Votes918.75%Audentes TherapeuticsOutperform Votes47069.12% Underperform Votes21030.88% Do institutionals and insiders believe in SLN or BOLD? 98.7% of Silence Therapeutics shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by insiders. Comparatively, 5.3% of Audentes Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has better earnings and valuation, SLN or BOLD? Audentes Therapeutics has lower revenue, but higher earnings than Silence Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilence Therapeutics$16.25M12.67-$53.82M-$1.57-4.38Audentes TherapeuticsN/AN/A-$49.43MN/AN/A Does the media refer more to SLN or BOLD? In the previous week, Silence Therapeutics had 2 more articles in the media than Audentes Therapeutics. MarketBeat recorded 2 mentions for Silence Therapeutics and 0 mentions for Audentes Therapeutics. Silence Therapeutics' average media sentiment score of 0.34 beat Audentes Therapeutics' score of 0.00 indicating that Silence Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Silence Therapeutics Neutral Audentes Therapeutics Neutral SummarySilence Therapeutics beats Audentes Therapeutics on 9 of the 14 factors compared between the two stocks. Ad Behind the MarketsWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.Click here for the ticker >>> Get Audentes Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLD vs. The Competition Export to ExcelMetricAudentes TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.76M$6.57B$5.14B$9.08BDividend YieldN/A2.98%5.09%4.23%P/E RatioN/A10.5089.8217.18Price / SalesN/A195.801,116.21116.95Price / CashN/A57.1642.8937.86Price / BookN/A5.094.784.78Net Income-$49.43M$151.83M$120.23M$225.60M Audentes Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLDAudentes Therapeutics1.7988 of 5 stars$2.59+2.8%$23.00+788.0%N/A$57.76MN/A0.00207High Trading VolumeSLNSilence Therapeutics3.1687 of 5 stars$8.28-2.8%$57.20+590.8%-58.7%$247.82M$31.55M-5.54100High Trading VolumeHURATuHURA BiosciencesN/A$5.79-13.3%$15.00+159.1%N/A$244.80MN/A0.00N/AAnalyst ForecastNews CoverageVSTMVerastem3.7857 of 5 stars$5.41-4.2%$12.50+131.1%-47.9%$240.80M$2.60M0.0050Analyst ForecastNews CoveragePGENPrecigen3.4635 of 5 stars$0.81+4.0%$7.00+766.8%-32.5%$236.52M$6.22M0.00202Negative NewsDMACDiaMedica Therapeutics0.8091 of 5 stars$5.33-1.3%$7.00+31.3%+127.3%$227.91MN/A0.0020News CoverageGap DownNLTXNeoleukin TherapeuticsN/A$23.72+7.9%N/A+53.1%$222.92MN/A-7.6390News CoverageHigh Trading VolumeMGNXMacroGenics3.543 of 5 stars$3.48-0.6%$7.63+119.1%-68.2%$218.41M$58.75M0.00430FULCFulcrum Therapeutics1.7128 of 5 stars$4.03+1.0%$9.33+131.6%-24.6%$217.37M$80.87M-13.00100BMEABiomea Fusion3.902 of 5 stars$5.90-3.3%$39.36+567.2%-71.0%$213.82MN/A0.0050Analyst ForecastCLYMClimb Bio3.3205 of 5 stars$3.12+3.3%$10.00+220.5%N/A$209.74MN/A-1.51N/ANews Coverage Related Companies and Tools Related Companies Silence Therapeutics Competitors TuHURA Biosciences Competitors Verastem Competitors Precigen Competitors DiaMedica Therapeutics Competitors Neoleukin Therapeutics Competitors MacroGenics Competitors Fulcrum Therapeutics Competitors Biomea Fusion Competitors Climb Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BOLD) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Audentes Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BOLD Stock Alerts